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792Objective: Autophagy is a cellular process by which damaged components are removed. Although autophagy
can result in cell death, when optimally regulated, it might be cardioprotective. Resveratrol is a naturally
occurring polyphenol also believed to be cardioprotective. Using a clinically relevant swine model of
metabolic syndrome, we investigated the effects of resveratrol on autophagy in the chronically ischemic
myocardium.
Methods: Yorkshire swine were fed a regular diet (n ¼ 7), a high cholesterol diet (n ¼ 7), or a high cholesterol
diet with supplemental resveratrol (n ¼ 6). After 4 weeks, an ameroid constrictor was surgically placed on the
left circumflex artery to induce chronic myocardial ischemia. The diets were continued another 7 weeks, and
then the ischemic and nonischemic myocardium were harvested for protein analysis.
Results: In the ischemic myocardium, a high cholesterol diet partly attenuated the autophagy, as determined by
an increase in phosphorylated mammalian target of rapamycin (p-mTOR) and a decrease in p70 S6 kinase
(P70S6K), lysosome-associated membrane protein (LAMP)-2, and autophagy-related gene 12-5 conjugate
(ATG 12-5; P< .05). The addition of resveratrol blunted many of these changes, because the p-mTOR,
P70S6K, and LAMP-2 levels were not significantly altered from those of the pigs fed a regular diet.
Other autophagy markers were increased with a high cholesterol diet, including light chain 3A-II and beclin
1 (P < .05). In the nonischemic myocardium, beclin 1 was decreased in the high cholesterol-fed pigs
(P<.05); otherwise no significant changes in protein expression were noted among the 3 groups.
Conclusions: In the chronically ischemic myocardium, resveratrol partly reversed the effects of a high
cholesterol diet on autophagy. This might be a mechanism by which resveratrol exerts its cardioprotective
effects. (J Thorac Cardiovasc Surg 2014;147:792-9)Autophagy is an adaptive process by which damaged
cellular components are removed or recycled. When
optimally regulated, autophagy is cardioprotective during
myocardial stress.1-4 When cardiac myocytes are hypoxic
or deprived of nutrients, autophagy will be upregulated,
and in the setting of caloric excess and metabolic
syndrome, autophagy will be diminished.3 With the
continued increase in the incidence of obesity and diabetes,
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The Journal of Thoracic and Cardiovascular Surgthe developed world.5,6 Metabolic syndrome not only
increases the risk of coronary artery disease but also
results in increased morbidity and mortality after ischemic
injury.7,8 In cardiac surgery patients, impaired autophagy
has been shown to result in unfavorable remodeling and
development of postoperative atrial fibrillation.9,10
Autophagy flux during cardiac surgery has also been
shown to correlate with surgical risk scores and the
crossclamp time.11 Novel mechanisms to regulate
autophagy can lead to a reduction of surgical risk and might
improve the operative outcomes.
In animal models, resveratrol supplementation has been
shown to mimic caloric restriction and to induce
autophagy.12,13 This naturally occurring polyphenol, found
in many berries, as well as in the grapes used to make red
wine, is believed to be cardioprotective in chronically
ischemic myocardium.14 In France, despite a diet high in
saturated fats, the mortality rates from cardiovascular disease
has been shown to be lower than in other countries. This
phenomenon, termed the ‘‘French Paradox,’’ is believed to
be related to the greater consumption of red wine and has
sparked interest in the potential benefits of resveratrol.15
The reported advantages of resveratrol are vast and
include increased longevity and benefits against cancer,
inflammation, and cardiovascular disease. The mechanismery c February 2014
Abbreviations and Acronyms
ACC ¼ regular diet control
ATG 12-5 ¼ autophagy-related-gene 12-5 conjugate
HCC ¼ high cholesterol control
HCRV ¼ high cholesterol plus resveratrol
LAMP ¼ lysosome-associated membrane protein
LC3 ¼ light chain 3
mTOR ¼ mammalian target of rapamycin
P70S6K ¼ p70 S6 kinase
p-mTOR ¼ phosphorylated mTOR
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remains under investigation.
In a swine model of metabolic syndrome and chronic
myocardial ischemia, we have previously demonstrated
that resveratrol prevented regional wall motion dysfunction
and preserved endothelium-dependent coronary function
and myocardial perfusion.14 However, no increase was
found in collateral formation, and the antiangiogenic
markers were actually increased.16 Using this model,
we have also demonstrated that in peripheral tissues
resveratrol improved inflammation and insulin and glucose
signaling.17,18 However, in the ischemic myocardium,
insulin signaling remained largely unchanged.19 In
rodents, resveratrol has been shown to prevent harmful
postinfarction remodeling through the induction of auto-
phagy.12,13 These results have suggested that resveratrol
acts on alternate pathways in a tissue-specific manner.
In the ischemic myocardium, regulation of autophagy
might be a potential mechanism by which resveratrol
supplementation prevents endothelial dysfunction and
cardiac remodeling. Thus, using a clinically relevant
swine model of metabolic syndrome, we sought to investi-
gate the effects of resveratrol on autophagy in chronic
myocardial ischemia.
METHODS
Animal Model and Surgical Interventions
Adult male Yorkshire miniswine (Parsons Research, Amherst, Mass)
were divided into 3 groups according to the daily diet fed during an
11-week period. The regular diet control (ACC) group was given no drug
and was fed a regular chow diet (n ¼ 7). The high cholesterol control
(HCC) group (n¼ 7) was given daily feedings of 500 g of a high cholesterol
diet providing 2248 kcal/d consisting of 75% regular chow, 4%
cholesterol, 17.2% coconut oil, 2.3% corn oil, and 1.5% sodium cholate.
The third group was fed the same diet as the HCC group but was also
supplemented with daily oral resveratrol, 100 mg/kg/d (HCRV group,
n ¼ 6; ChromaDex, Irvine, Calif). The feedings were observed to confirm
complete consumption of the food and supplement. After 4 weeks of
dietary adherence, the pigs in both study groups (HCC and HCRV groups)
underwent surgical placement of a titanium (1.75-2.25 mm in diameter)
ameroid constrictor (Research Instruments SW, Escondito, Calif) on the
proximal left circumflex coronary artery.
The anesthesia used for the procedures and the perioperative analgesia
and antibiotic prophylaxis have been previously described.14 The methodsThe Journal of Thoracic and Cafor myocardial perfusion analysis and coronary angiography have also
been previously described in these pigs.14
At 7 weeks after ameroid placement, the pigs were killed, and their
hearts were harvested. Tissue samples from the chronically ischemic
myocardium in the left circumflex coronary artery territory and
nonischemic myocardium were rapidly frozen in liquid nitrogen for
molecular studies. The Institutional Animal Care and Use Committee of
the Rhode Island Hospital approved all the experiments. The pigs were
cared for in compliance with the ‘‘Principles of Laboratory Animal
Care’’ formulated by the National Society for Medical Research and the
‘‘Guide for the Care and Use of Laboratory Animals.’’
Western Blots
Radioimmunoprecipitation assay buffer (Boston BioProducts,
Worcester, Mass) or 2% sodium dodecyl sulfate-based detergent was
used to isolatewhole cell lysates from homogenized tissue. The myocardial
samples from the chronically ischemic territories and nonischemic
territories were assessed separately. The total protein concentration was
determined using the bicinchoninic acid assay (Pierce, Thermo Scientific,
Rockford, Ill). A total of 40 mg of total protein was fractionated using 4%
to 12% Bis-Tris gel electrophoresis (NuPage Novex Mini Gel, Invitrogen,
Carlsbad, Calif). The protein samples were transferred to polyvinylidene
difluoride membranes (Millipore, Bedford, Mass). Each membrane was
incubated overnight at 4C with the following primary antibodies:
mammalian target of rapamycin (mTOR), phosphorylated mTOR
(p-mTOR), p70 S6 kinase (P70S6K), beclin 1, autophagy-related-gene
12-5 conjugate (ATG12-5), light chain 3 (LC3)A-II, LC3B-II, and
lysosome-associatedmembrane protein (LAMP)-1 (all fromCell Signaling
Technology, Danvers, Mass) and LAMP-2 (Life Technologies, Grand
Island, NY). The lysates made in radioimmunoprecipitation assay buffer
were used for Western blotting of mTOR and p-mTOR. All the other
primary antibodies were incubated on membranes prepared with lysates
isolated in sodium dodecyl sulfate. The membranes were incubated with
the appropriate horseradish peroxidase-linked secondary antibody at
room temperature for approximately 1 hour (Jackson ImmunoResearch,
West Grove, Pa). The immune complexes were visualized using enhanced
chemiluminescence, and the images were captured with a digital camera
system (G-Box Syngene, Cambridge, UK). All membranes were
probed with glyceraldehyde-3-phosphate dehydrogenase (Cell Signaling
Technology) to correct for protein loading.
Statistical Analysis
The Western blot bands were quantified with densitometry using
Image-J software (National Institutes of Health, Bethesda, Md).
The probability values for the Western blot data are reported from 2-way
analysis of variance followed by a post hoc Bonferroni test of the
densitometry arbitrary units. The Western blot results are expressed as
the x-fold change  standard error of the mean compared with the ACC
group (Tables 1 and 2 and Figure 2).
RESULTS
Animal Model
All the pigs included for analysis survived the study to
completion. As previously reported,14 7 weeks after
ameroid placement, no change was found in the myocardial
blood flow at rest. However, when stressed with ventricular
pacing, the adjusted myocardial blood flow in the ischemic
area was improved in the HCRV group compared with the
HCC group.14 Also, 7 weeks after placement of the ameroid
constrictor, coronary catheterization demonstrated that all
the pigs had 99% to 100% occlusion of the left circumflex
coronary artery.14rdiovascular Surgery c Volume 147, Number 2 793
TABLE 1. Protein expression in ischemic myocardium
Target ACC group HCC group HCRV group P value
mTOR 1  0.252 2.09  0.534 1  0.207 .083
p-mTOR 1  0.218 4.09  0.555 2.19  0.560 .0006*,y
P70S6K 1  0.279 0.25  0.062 0.40  0.123 .017*
Beclin 1 1  0.257 2.55  0.408 2.66  0.435 .0083*,z
ATG 12-5 1  0.353 0.12  0.063 0.06  0.015 .0028*,z
LAMP-1 1  0.306 1.24  0.182 0.74  0.138 .34
LAMP-2 1  0.248 0.26  0.041 0.43  0.129 .013*
LC3A-II 1  0.087 3.06  0.725 1.74  0.274 .017*
LC3B-II 1  0.158 0.96  0.238 1.62  0.488 .28
Protein expression listed as x-fold change  standard error of the mean compared
with the ACC group. One-way analysis of variance performed to determine the
P value. Bonferroni multiple comparison tests were performed. ACC, Regular diet
control; HCC, high cholesterol control; HCRV, high cholesterol plus resveratrol;
mTOR, mammalian target of rapamycin; p-mTOR, phosphorylated mTOR;
P70S6K, p70 S6 kinase; ATG 12-5, autophagy-related gene 12-5 conjugate;
LAMP, lysosome-associated membrane protein; LC3, light chain 3. *Significant
difference between ACC and HCC groups. ySignificant difference between HCC
and HCRV groups. zSignificant difference between ACC and HCRV groups.
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initiation of the diets at 4 and 11 weeks. No significant
differences were found in the body mass index among the
pigs in all 3 groups after 4 weeks (Figure 1). After 11 weeks,
however, the body mass index was significantly higher in
the HCC group than in either the ACC group or HCRV
group (P ¼ .0042; Figure 1). After 11 weeks, 50 g of
dextrose was administered intravenously. The blood
glucose levels measured 30 minutes after the dextrose
infusion were significantly greater in the HCC group than
in either the ACC or HCRV group (P ¼ .014; Figure 1).
Western Blots
In the ischemic myocardium, the pigs given a high
cholesterol diet alone (HCC group) demonstrated a fourfold
increase in p-mTOR and a decrease in P70S6K compared
with the pigs fed a regular diet (ACC group; P ¼ .0006TABLE 2. Protein expression in nonischemic myocardium
Target ACC group HCC group HCRV group P value
mTOR 1  0.154 1.64  0.272 0.94  0.383 .16
p-mTOR 1  0.172 1.82  0.478 0.92  0.100 .22
P70S6K 1  0.199 1.05  0.112 1.03  0.170 .98
Beclin 1 1  0.163 0.56  0.039 0.75  0.068 .0098*
ATG 12-5 1  0.332 0.73  0.133 0.87  0.291 .72
LAMP-1 1  0.123 0.92  0.094 0.97  0.176 .89
LAMP-2 1  0.201 0.61  0.062 0.69  0.197 .18
LC3A-II 1  0.149 0.70  0.106 0.88  0.165 .28
LC3B-II 1  0.135 0.66  0.051 0.86  0.123 .063
Protein expression listed as x-fold change  standard error of the mean compared
with the ACC group. One-way analysis of variance performed to determine the
P value. Bonferroni multiple comparison tests were performed. ACC, Regular diet
control; HCC, high cholesterol control; HCRV, high cholesterol plus resveratrol;
mTOR, mammalian target of rapamycin; p-mTOR, phosphorylated mTOR;
P70S6K, p70 S6 kinase; ATG 12-5, autophagy-related gene 12-5 conjugate;
LAMP, lysosome-associated membrane protein; LC3, light chain 3. *Significant
difference between ACC and HCC groups.
794 The Journal of Thoracic and Cardiovascular Surgand P ¼ .017, respectively; Table 1 and Figure 2). The
downstream markers of autophagy, including LAMP-2
and ATG 12-5, were also decreased in the HCC group
compared with the ACC group (P ¼ .013 and P ¼ .0028
respectively; Table 1 and Figure 2).
The pigs in the HCRV group had no significant changes
in the protein levels of p-mTOR, P70S6K, and LAMP-2
compared with the ACC group (Table 1 and Figure 2). Other
markers of autophagy were increased in the ischemic
myocardium in the pigs fed a high cholesterol diet,
including LC3A-II in the HCC group (P¼ .017) and beclin
1 in the HCC and HCRV groups (P ¼ .0083; Table 1 and
Figure 2).
In the nonischemic myocardium, beclin 1 was decreased
in the HCC group compared with the ACC group
(P ¼ .0098; Table 2). Otherwise, no significant changes
were found in the nonischemic myocardium among the
3 groups (Table 2).
DISCUSSION
The results from the present study have demonstrated that
in a swine model of metabolic syndrome, resveratrol sup-
plementation partially reverses many of the alterations in
autophagy signaling caused by a high cholesterol diet on
chronically ischemic myocardium. Previous studies from
our laboratory showed resveratrol to modify the risk factors
for coronary artery disease in a similar swine model. Pigs
fed a high cholesterol diet supplemented with resveratrol
had improved global ventricular functioning, increased
microvascular relaxation, and reduced markers of inflam-
mation.14,17,20 However, the mechanism by which
resveratrol exerts these effects remains unclear and likely
has several points of regulation, including autophagy.
Autophagy is a highly regulated process that
begins with the formation of an ‘‘autophagosome.’’ This
double membrane structure engulfs cytoplasmic cargo
marked for destruction. The outer membrane of the
autophagosome fuses with a lysosome, forming an
‘‘autolysosome’’—where the cargo is ultimately degraded.3
Several specific proteins markers associated with this
process have been well described. Early regulatory
proteins, such as mTOR and p70S6K, highlight the
relationship of autophagy to other homeostatic processes,
because these proteins have been found downstream in
insulin signaling and mitogen-associated protein kinase
pathways.21,22 Other, more specific and essential, markers
for autophagy include beclin 1, ATG 12-5, and LAMP.
Beclin 1 is essential for autophagy induction. The
conjugation of ATG 12 to ATG 5 is required for the
initial double membrane formation. LC3 and LAMP
are critical downstream markers that are ultimately
required to form and stabilize the autolysosome
(Figure 3).1,23-26 Significant evidence has shown that
autophagy is cardioprotective during ischemic stress.1-4ery c February 2014
FIGURE 1. Body mass index (BMI) and blood glucose level. A, No difference was found in the BMI between the 2 groups when calculated 4 weeks after
initiation of the respective diets. B, At 11 weeks, a significant differences was found in the BMI in the high cholesterol control (HCC) group compared with
the regular diet control (ACC) group and the high cholesterol plus resveratrol (HCRV) group (P ¼ .0042). C, The blood glucose level was measured at 11
weeks, 30minutes after 50 g of dextrose had been given intravenously. The blood glucose level was significantly greater in the HCC group than in the ACC or
HCRV group (P ¼ .0014). One-way analysis of variance was performed to determine the P values. Bonferroni multiple comparison tests were performed.
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ischemic myocardium, autophagy in excess has also been
shown to be harmful.4,25 This intricate process is
influenced by many factors, and its markers become
concentrated and redistributed at different stages.27 Thus,
a cautious approach must be used when interpreting results
involving the markers of autophagy.
The induction of autophagy involves the inhibition of
mTOR. This protein is involved in multiple molecular
signaling pathways. When phosphorylated, mTOR is
activated and becomes an effective downregulator of
autophagy. This is known to occur in the setting of caloric
excess and hyperlipidemia.22 Consistent with this, our
results have demonstrated a fourfold increase in p-mTOR
in the ischemic myocardium of the high cholesterol-fed
pigs compared with those fed a regular diet. However,
when the high cholesterol-fed pigs were given resveratrol,
the p-mTOR levels were lower, more closely matching
the levels in the pigs fed a regular diet (Table 1 and
Figure 2). It appears that resveratrol prevents the activation
of mTOR seen with a high cholesterol diet, possibly
reducing the inhibition of autophagy at this early regulatory
step (Figure 3).
A downstream inhibitor of mTOR is p70S6K.21,28 Our
study has shown that a high cholesterol diet alone
significantly decreases the p70S6K levels, and resveratrol
supplementation returned the p70S6K levels closer to
baseline levels. With the increase in p70S6K resultingThe Journal of Thoracic and Cafrom resveratrol supplementation, mTOR activation was
likely downregulated, thus promoting autophagy signaling
downstream (Figure 3).
In our study, the beclin 1 levels were significantly
increased in the ischemic cardiomyocytes of the pigs fed
a high cholesterol diet with and without resveratrol. Beclin
1 and its associated complexes regulate the autophagy
pathway at multiple stages and in a tissue-specific fashion.
These interactions are often transient and unstable and
can result in an increase or a decrease in autophagy.
Beclin 1-independent autophagy has also been described.24
Thus, although it is an important marker of autophagy, the
interpretation of beclin 1 levels can be difficult, and
elevated levels of beclin 1 will not necessarily indicate
increased autophagy.29
Similar to beclin 1, resveratrol supplementation does not
seem to significantly alter the ATG 12-5 levels. We found a
significant decrease in ATG 12-5 in the high cholesterol-fed
pigs with and without resveratrol supplementation
compared with the regular diet controls. ATG 12-5 is
essential for the expansion and completion of the
autophagosome. LAMP-2, also involved in completion of
the autophagosome, was significantly decreased only
in the high cholesterol-fed pigs that were not given
resveratrol27,29 (Figure 3).
We found the autophagy marker LC3A-II to be increased
threefold in the high cholesterol-fed pigs compared with the
pigs fed a regular diet. The high cholesterol-fed pigsrdiovascular Surgery c Volume 147, Number 2 795
FIGURE 2. Protein expression in ischemic myocardium x-fold change standard error of the mean compared with the regular diet control (ACC) group.
One-way analysis of variance was performed to determine the P value. Bonferroni multiple comparison tests were performed.mTOR,Mammalian target of
rapamycin; pmTOR, phosphorylated mammalian target of rapamycin; P70S6K, p70 S6 kinase; ATG 12-5, autophagy-related gene 12-5 conjugate;
LAMP, lysosome-associated membrane protein; LC3, light chain 3.
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more similar to those of the pigs fed a regular diet. The
microtubule-associated protein LC3 is an ubiquitin-like
molecule that is a known specific marker for autophagy.
LC3-II plays an integral role not only in the formation of
the autophagosome, but also in selecting the cytosolic
components for degradation1,26,28,29 (Figure 3). LC3-II
upregulation indicates either an increase in autophagosome
formation or a decrease in degradation. No significant
changes were found in the LC3A-II levels in the
nonischemic myocardium, and no significant changes
were found in the LC3B-II levels in the ischemic and
nonischemic myocardium.
Study Limitations and Future Directions
The present study had several limitations. Because we
used a large animal model, the number of pigs in each group
was kept to a minimumwhile allowing appropriate power to
observe the statistical significance. Thus, the interpretation796 The Journal of Thoracic and Cardiovascular Surgof the results must be kept within this context. Although the
porcine cardiac physiology is similar to that of humans, the
pathologic alterations and response to exogenous factors
could differ among species. Furthermore, we were unable
to comment on the differences in the treatment length or
dose-mediated response of resveratrol treatment, because
the pigs in the present study received a fixed, relatively
high dose of resveratrol. Interpreting the levels of
autophagy markers is complicated by their constant flux
and multiple points of regulation. Moreover, the timing
and measure necessary for autophagy to be cardioprotective
remains unclear. Importantly, we did not directly measure
autophagy. Instead, as described in similarly designed
studies, we used Western blotting to measure the specific
and essential markers of the process. The reference standard
for directly measuring autophagy is electron microscopy,
with which the autolysosome is visualized at different
stages in its development. An important criticism of
electron microscopy is that it does not allow objective andery c February 2014
FIGURE 3. Schematic model of the autophagy pathway demonstrating several relevant markers of autophagy that are potentially influenced by a high
cholesterol diet and as possible points of regulation by resveratrol (RV). p70S6K, p70 S6 kinase; LAMP, lysosome-associated membrane protein;
ATG 12-5, autophagy-related gene 12-5 conjugate; LC3, light chain 3.
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a ubiquitous, homeostatic process.2,4,11,29-31 For the
purposes of our study, a quantitative measure was
necessary; thus, Western blotting was used. Future studies
aimed at clarifying the mechanisms relating resveratrol
and autophagy are needed. Specifically, the overlap of
autophagy and other molecular pathways such as
apoptosis should be examined further. Also, because
autophagy is a dynamic process, examining it at different
points will help elucidate its effects. Although we have
emphasized the clinical relevance of a large animal
model, attempting to replicate these studies in other
species and in cell cultures might help clarify the
underlying mechanisms involved.
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Dr Michael P. Fischbein (Stanford, Calif). Excellent presenta-
tion. For my first question, did you look for autophagy directly in
your heart specimens rather than just indirectly by measuring the
upstream and downstream markers that you showed today?
Dr Sabe. Although we did look at specific essential markers of
autophagy, immunoblotting in and of itself is an indirect measure,
as you alluded. If we wanted to study this directly, we have to use
electron microscopy. That is actually the reference standard for
studying autophagy. How that is done is one looks for the
autophagosome vacuole in formation at different stages using
electron microscopy, and, as one can imagine, that requires quite
a bit of experience and expertise. One of the greatest criticisms
of this technique is that because autophagy is a ubiquitous
process (ie, it occurs in cells all the time), using electron
microscopy to study it is not objectively quantifiable, and the
specificity might not be ideal. Thus, our method we thought was
reproducible, something we could objectively quantify, and was
specific.
Dr Fischbein. The second question is biologic proof of
concept that autophagy is actually playing a role in your ischemic
myocardium. Did you consider blocking autophagy?
Dr Sabe. Because it is an essential process, you cannot
completely block it in a large animal model such as this. That
being said, other groups have had knockout mice with essential
markers ‘‘blocked out.’’ Some of the criticism of this has been
that with the knockout mice, compensatory mechanisms have
occurred that might have confounded the results.
Another technique is actually just diminishing autophagy with
medications, such as chloroquine, and that is certainly something
that has been done in mouse models and something that we could
definitely try. Also, just to clarify, when they did do that in
the study in which they used chloroquine, the infarct size
was increased and the ventricular remodeling after infarct was
worse.798 The Journal of Thoracic and Cardiovascular SurgDr Fischbein. Also, if autophagy is as protective as you are
suggesting, did you see an actual decrease in cardiomyocyte
apoptosis or necrosis with your treatment?
Dr Sabe.That is a good question. I think the key to that question
is ‘‘whether autophagy is good?’’ and ‘‘how to prove it by studying
apoptosis and necrosis.’’ We began studying apoptosis, and we do
have some preliminary data. As I mentioned, the key question is
where apoptosis might overlap with autophagy signaling. Some
of that data will be coming, and I think it will be interesting.
As far as studying necrosis, we have not done that. That can be
done, obviously, with tissue staining. Again, how well or easy
that is to quantify would be questionable. However, using
magnetic resonance imaging in this animal model and even
clinically looking at scar tissue would also be interesting and
another future direction to move toward.
Dr Fischbein. Last question is, in all our research, we are
always looking for translational potential, and so, how would
you predict that we are going to use this drug clinically?
Dr Sabe. That is a great question. At this point, I think more
preclinical studies are needed. That is part of the reason we did
this in a clinically relevant large animal model, which we think
more readily translates to our patient population. That said,
resveratrol is available over the counter as an herbal supplement
and has been for a long time. Also, resveratrol analogs have
been, and are currently being, used safely in clinical trials
investigating the potential benefits against cancer and dementia.
I would design a study giving resveratrol for perhaps several
weeks before coronary artery bypass grafting in diabetic patients.
It would be interesting to study the difference between patients
with poorly controlled diabetes and those with well-controlled
diabetes. I think you could also do that in a broader scope in a
clinical trial, just giving it to patients with angina and diabetes.
Somebody had alluded to this earlier, but at this point I do not
see resveratrol being used in its current form. You might need a
stronger analog or a more potent analog. That might be because
resveratrol is more likely a disease-modifying drug that reduces
the risk factors. Also, a number of these patients have already
been identified and are receiving insulin and are taking metformin
and statins. They might already be receiving the benefits of
resveratrol. I think in the future we are going to be using more
potent analogs once we have a better understanding of how this
works.
Dr Fischbein. Thank you. Nice presentation.
Dr Frank A. Baciewicz, Jr (Detroit, Mich). Are there clinical
trials already studying autophagy in the short term just for
coronary cases and other cardiac surgery cases? Are you aware
of any studies?
Dr Sabe. Just studying autophagy in and of itself, yes. Actually,
they were studying autophagy during bypass surgery before and
after cardioplegia using atrial tissue sampling. They only
considered autophagy in these studies, not with resveratrol, but
just specifically studying autophagy and its upregulation in
different patients during surgery, before and after cardioplegia.
That was recently published.
Dr Baciewicz. What medications are they using?
Dr Sabe. I am not sure whether these patients were getting
any additional medications—I do not think they were receiving
anything. I think they were specifically just studying atrialery c February 2014
Sabe et al Evolving Technology/Basic Sciencesampling and measuring autophagy as more of what is occurring
during bypass before and after cardioplegia/cardiopulmonary
bypass and whether autophagy is a critical process and how
autophagy is affected and how that is related to patient outcomes.
Dr Baciewicz. I thought they gave drugs to try to alter the
autophagy rate, and they showed some difference.
Dr Sabe. I am thinking of the report by Dr Mentzer. I do not
think they did, but I am not sure. Is that what you are referring to?
Dr Baciewicz. Yes.
Dr Sabe. I do not believe they did that, but I would have to
review it again. I do not think they did. I do not think they gave
any medication. I think they were just studying autophagy and
whether it is induced after surgery as more just to determine
what happens, and whether it is good or bad.The Journal of Thoracic and CaDr Y. Joseph Woo (Philadelphia, Pa). Did you prove
hypocholesteremia in the latter 2 groups?
Dr Sabe. Yes, we did. That was actually in a previous publica-
tion, and we did measure the triglyceride and cholesterol levels.
Dr Woo. Did you also measure the caloric intake?
Dr Sabe. These pigs were given either their regular chow or a
fatty diet. The fatty diet was not really a burger and fries, such
as on my slides—it was a fat supplemented diet. Also, the pigs
would eat everything—that was observed to be sure. The diet
was regimented with exactly 2248 kcal for the high cholesterol
group.
DrWoo. Thus, the ingestion of resveratrol did not increase their
appetite or their caloric intake?
Dr Sabe. No. They were given a fixed diet.rdiovascular Surgery c Volume 147, Number 2 799
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